Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases

• Autorzy: Dorszewska J. , Florczak J. , Rozycka A. , Kempisty B. , Jaroszewska-Kolecka J. , Chojnacka K. , Trzeciak W. H. , Kozubski W.
• Języki publikacji: EN

Abstrakty

EN

Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), are accompanied by increased levels of 8-oxo-2'deoxyguanosine (8-oxo2dG) and alterations in levels of homocysteine (Hcy), methionine (Met), and cysteine (Cys). Hcy may undergo remethylation due to involvement of MTHFR, MTR and MTHFD1 proteins. Present studies are aimed at determination of 8-oxo2dG, Hcy, Met, and Cys in AD and PD patients as well as in control groups, using HPLC/EC/UV, as well as estimation, by restriction analysis, frequency of following gene polymorphisms: MTHFR (C677T, A1298C, G1793A), MTHFD1 (G1958A), and MTR (A2756G). In AD there were significant differences of the levels of only Cys (GG, MTHFR, G1793A) and Met/Hcy (AA, MTHFD1, G1958A) whereas in PD there were more significant differences of the levels of thiols: Hcy [MTHFR: CT (C677T) and GG (G1793A); MTR, AG (A2756G)], Met [MTR, AA (A2756G)], Cys [MTR, AG (A2756G)], and Met/Hcy [MTHFR: CC, CT (C677T) and AA (A1298C), and GG (G1793A); MTHFD1 AA (G1958A); MTR AA (A2756G)]. Significant differences in the levels of Cys/Hcy, MTHFD1 GA (G1958) were varied between AD and PD groups. The results indicate that of the enzymes studied only polymorphisms of folate-dependent enzyme MTHFD1 have pointed to significant differences in intensity of turnover of circulating thiols between AD and PD patients.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2007
• Tom: 67
• Numer: 2
• Opis fizyczny: p.113-129,fig.,ref.

Twórcy

autor

Dorszewska J.

• Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Florczak J.

• Department of Neurology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Rozycka A.

• Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Kempisty B.

• Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Jaroszewska-Kolecka J.

• Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Chojnacka K.

• Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Trzeciak W. H.

• Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan, Poland

autor

Kozubski W.

• Department of Neurology, Poznan University of Medical Sciences, 49 Przybyszewskiego St., 60-355 Poznan, Poland

Uwagi

PL

Rekord w opracowaniu